Inflammasome has recently been awarded a $1.3 million grant from the Bill and Melinda Gates Foundation to develop dual bioerodible sustained-release implants that combine drugs for HIV prevention and birth control. The implant will deliver a steady dose of islatravir for HIV prevention and the hormone levonorgestrel for birth control . . .

Get GEN Edge Today!

See More on the Edge

Continue reading this article and more
with a GEN Edge subscription

Start Your 30-Day Free Trial Now

Log In Join GEN Edge

The post Inflammasome Therapeutics Takes On Sustained Drug Delivery appeared first on GEN – Genetic Engineering and Biotechnology News.